OmniComm Systems Releases IRTMaster Version 5.2
OmniComm Systems, Inc., an Anju Software Company and strategic software solutions provider to the life sciences industry, has announced its release of IRTMaster Version 5.2, an enhanced product offering to complement their comprehensive eClinical suite. IRTMaster is a fully configurable Interactive Responsive Technology (IRT) system that enables subject screening and randomization, clinical supply management, and investigational product assignment at designated drug dispensing visits. Its unique IRTBuilder workflow allows a single user to implement protocol-specific requirements through a collection of configurable, pre-validated modules without custom programming, dramatically shortening timelines for initial builds and mid-study change requirements.
IRTMaster by itself offers a choice of randomization methodologies (including permuted block, dynamic minimization and Zelen), use of multiple warehouses for managing site supplies, configurable user interface in multiple languages, email notifications and alerts, and streamlined user administration enabling management of multiple studies under a single logon. The system integrates seamlessly with TrialMaster EDC with near-real- time, bi-directional integration, allowing data to pass back and forth, eliminating redundancy in data entry for investigative sites. IRTMaster’s ability to act as a stand-alone system or in conjunction with TrialMaster EDC makes it a desirable solution for customers who require flexibility and scalability in their clinical trial development.
“IRTMaster is specifically designed to reduce the burden of setting up randomization and managing drug supplies within a clinical trial,” said Stephen Johnson, chief revenue officer at OmniComm. “This next generation IRT solution is fully self-service, allowing our clients to either set up randomization and drug shipments on their own, or as a service leveraging our expert clinical analysts. Either way, the configurable and pre-validated modules significantly shorten the time it takes to implement compared to competing IRT solutions.”
IRTMaster joins TrialMaster, TrialOne, AutoEncoder and Acuity as one of OmniComm’s principal offerings available through their fully hosted Software-as-a-Service (SaaS) model or Enterprise Enablement deployment model, and supported by their in-house, round-the-clock customer support team.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
